All Mike Doustdar articles
-
News
Obesity drug competition fuels Novo Nordisk restructure
The company’s CEO says the shift will help prioritise investment into obesity and diabetes, the company’s leading therapy areas.
The company’s CEO says the shift will help prioritise investment into obesity and diabetes, the company’s leading therapy areas.